Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$0.28 - $0.44 $1,008 - $1,584
-3,600 Reduced 23.08%
12,000 $5,000
Q3 2022

Nov 14, 2022

SELL
$0.28 - $0.41 $308 - $451
-1,100 Reduced 6.59%
15,600 $4,000
Q2 2022

Aug 11, 2022

SELL
$0.25 - $0.73 $400 - $1,168
-1,600 Reduced 8.74%
16,700 $6,000
Q1 2022

May 11, 2022

SELL
$0.55 - $1.47 $990 - $2,646
-1,800 Reduced 8.96%
18,300 $12,000
Q4 2021

Feb 11, 2022

SELL
$1.29 - $2.36 $40,893 - $74,812
-31,700 Reduced 61.2%
20,100 $26,000
Q3 2021

Nov 12, 2021

SELL
$1.81 - $2.7 $950 - $1,417
-525 Reduced 1.0%
51,800 $112,000
Q1 2021

May 14, 2021

SELL
$2.34 - $3.44 $702 - $1,032
-300 Reduced 0.57%
52,325 $137,000
Q4 2020

Feb 08, 2021

BUY
$1.91 - $5.63 $100,513 - $296,278
52,625 New
52,625 $146,000

Others Institutions Holding SIOX

About Sio Gene Therapies Inc.


  • Ticker SIOX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,975,200
  • Description
  • Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...
More about SIOX
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.